8th December 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Akeso to out license $5 Billion bispecific antibody to Summit Therapeutics

Biopharma company Akeso Inc. has declared that it is going to partner with Summit Therapeutics Inc. in a deal worth $5 Billion by out-licensing its blockbuster bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for manufacturing and commercialization in the US, Europe, Canada, and Japan.

LifeCell and HaystackAnalytics signs pact to scale-up TB whole genome sequencing in India

Healthcare solution providers LifeCell in collaboration with HaystackAnalytics which is a genomics-based health-tech startup announced the launch of a revolutionary genetic test – TB (Omega TB) that will aid in the genetic testing of TB patients.

Export benefits under tax refund scheme expanded to pharma, steel items and chemicals

On Wednesday, the government extended export benefits under the tax refund scheme (RoDTEP) to Pharmaceutical products, steel and iron and chemicals for a certain period of time to increase the export of these goods.

GSK receives approval from regulatory authority to launch Shingles Vaccine in India

GSK is all set to launch new Shingles Vaccine in India for those who are above 50 years of age. The company has got regulatory approvals from India’s drug regulatory authorities and are planning to launch it in the market next year.

Essential pharma acquires Janssen Pharma's antipsychotic drug 'HALDOL'

Essential pharma which is an international specialty pharma group announced the acquisition of ‘Haldol’ Decanoate (haloperidol decanoate) from Janssen Pharmaceuticals indicated for the treatment of Schizophrenia and some other psychiatric conditions.

French drug agency under investigation over misleading information about thyroid drug

The France-based ANSM drug agency said it is under formal investigation because of suspicion of issuing misleading information concerning Merck’s thyroid drug Levothyrox, adding it challenged the provisional charges.

IPC alerts about Norfloxacin induced skin hyperpigmentation

The Indian Pharmacopoeia Commission (IPC) has flagged a drug safety alert stating that the antibacterial Norfloxacin is related to an adverse reaction known as skin hyperpigmentation.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?